8-K: Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Trial for Obstructive Sleep Apnea Treatment

Incannex Healthcare announces the completion of Phase 2 patient enrollment in its RePOSA Phase 2/3 study of IHL-42X, an oral treatment for Obstructive Sleep Apnea (OSA), with topline data expected in the first half of 2025.

Summary

• Incannex Healthcare has completed Phase 2 enrollment in the global Phase 2/3 RePOSA study of IHL-42X for treating Obstructive Sleep Apnea (OSA).
• IHL-42X is an oral fixed-dose combination medicine designed to reduce breathing interruptions during sleep and improve sleep quality.
• The Phase 2 study is a four-week, dose-finding study comparing two dose strengths of IHL-42X (2.5 mg dronabinol/125 mg acetazolamide and 5 mg dronabinol/250 mg acetazolamide) to placebo.
• More than 120 patients were enrolled across 11 study sites in the U.S.
• Topline Phase 2 clinical data is expected in the first half of 2025.
• The Phase 3 expansion study will evaluate the selected IHL-42X dose over 52 weeks, enrolling approximately 440 patients across four treatment arms.
• The study aims to support future regulatory submission and provide a new treatment option for OSA patients.
• At least 560 patients will be recruited, with a total of 355 patients receiving IHL-42X over the course of the study.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the successful completion of Phase 2 enrollment and anticipation of Phase 2 data. However, risks associated with clinical trials and market competition temper the overall optimism.

Positives

• The completion of Phase 2 enrollment in the RePOSA trial was achieved rapidly, indicating strong interest and a pressing need for effective OSA treatments.
• IHL-42X targets underlying causes of OSA, potentially offering meaningful benefits to patients.
• The Phase 2/3 study follows a successful pharmacokinetic (PK) study, supporting a future FDA 505(b)(2) new drug application (NDA).
• Phase 2 trials sites will be rolled over into the Phase 3 expansion study, allowing for an efficient transition and minimizing downtime between study phases.
• In a prior Australian Phase 2 clinical trial, IHL-42X was shown to reduce the Apnea-Hypopnea Index (AHI) in all dosage strengths, with the lowest dose reducing AHI by an average of 51 percent relative to baseline.

Negatives

• There is currently no approved pharmaceutical therapy specifically for the treatment of OSA, highlighting the unmet need but also the challenges in developing such a treatment.
• Current treatment options like CPAP devices have significant drawbacks in terms of long-term use and patient compliance.

Risks

• The success of the Phase 3 trial is not guaranteed, and results may not support regulatory submission.
• Competition from other providers and products could impact the market for IHL-42X.
• The company's ability to raise capital to fund continuing operations is subject to market conditions and investor sentiment.
• The company's compliance with the various evolving and complex laws and regulations applicable to its business and its industry is not guaranteed.

Future Outlook

Incannex anticipates reporting topline clinical data from the Phase 2 portion of the RePOSA study in the first half of 2025 and progressing to the larger Phase 3 trial.

Management Comments

• 'We are excited to have achieved this milestone and deeply grateful to our investigators, site coordinators, and, especially to the sleep apnea patient community for its support,' said Lou Barbato, M.D., Chief Medical Officer of Incannex.
• Mark Bleackley, Ph.D., Chief Scientific Officer of Incannex, stated that they are eager to report topline clinical data from Phase 2 and progress to Phase 3 as swiftly as possible.
• Mira Baron, M.D., a lead investigator for the RePOSA Phase 2/3 trial, noted the strong interest underscores the pressing need for more effective pharmaceutical options to manage OSA.

Industry Context

The announcement addresses the significant unmet need for pharmaceutical treatments for OSA, as current options like CPAP have limitations in patient compliance. The development of IHL-42X represents a novel approach targeting the underlying pathophysiology of OSA, potentially filling a longstanding treatment gap.

Comparison to Industry Standards

• Current treatments for OSA include CPAP devices and, for obese patients, injectable GIP/GLP-1 agonists, but these have limitations in long-term use and patient compliance.
• Surgical options exist but have varying success rates and potential complications.
• IHL-42X aims to provide a pharmaceutical alternative, targeting physiological pathways associated with airway obstruction and CO2 accumulation, which is a different approach compared to existing treatments.

Stakeholder Impact

• Shareholders may react positively to the progress in clinical development.
• Patients with OSA could benefit from a new treatment option if IHL-42X proves effective and safe.
• Clinicians may have a new tool to manage OSA if the drug is approved.

Next Steps

• The company will analyze the Phase 2 data to determine the optimal dose strength for the Phase 3 trial.
• Incannex plans to initiate the Phase 3 expansion study, enrolling approximately 440 patients.
• The company anticipates reporting topline clinical data from the Phase 2 portion of the RePOSA study in the first half of 2025.

Key Dates

Keywords

IHL-42X, Obstructive Sleep Apnea, OSA, RePOSA, Clinical Trial, Phase 2, Phase 3, Incannex Healthcare, Dronabinol, Acetazolamide, Treatment, Pharmaceutical